I’m not a big fan of rules (as my high school record will tell you), but I am a fan of effective regulation. That same contradiction is reflected in debates around the world, prompted simultaneously by tragedy where rules seem insufficient, and frustration where common sense seems overbearing. We collectively seesaw between these views because regulation is a balance between societal safeguards and promoting individual endeavour, and judgments around this balance change over time and context.Read more
“Innovative diabetes treatments have transformed the lives of patients around the world, and this study draws attention to the need for governments and healthcare systems to adequately address these treatment needs to support healthy and productive lives for all."Read more
"We want the best for all cancer patients. The role of the Cancer Drugs Fund is to fund medicines that have been rejected or not approved by NICE in order to ensure that NHS patients have improved access, as they do in other EU countries. We share the desire of the Public Accounts Committee to achieve a sustainable, affordable solution that provides rapid access to new medicines for NHS patients."Read more
We welcome the publication of the Carter Review, published by the Department of Health today, and its recommendations for medicines optimisation. We are pleased that the Review, and its recommendations, emphasise the importance of a collaborative process, and recognises where industry contributes to developing efficient and innovative solutions to the challenges facing the NHS.Read more
Our website is not compatible with Internet Explorer 8. If you are experiencing problems with scrolling please upgrade to a later version or use another browser.